Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/3/23 Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference 12/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/28/22 Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy 11/23/22 Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference 11/2/22 Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments 10/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/26/22 Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico 10/26/22 Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey 10/26/22 Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 788 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/3/23 Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference 12/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/28/22 Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy 11/23/22 Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference 11/2/22 Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments 10/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/26/22 Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico 10/26/22 Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey 10/26/22 Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 788